SECsense Logo

Immunic, Inc. 8-K Filing: Key Insights & Financial Overview as of February 2025

$IMUX
Form 8-K
Filed on: 2025-02-20
Source
Immunic, Inc. 8-K Filing: Key Insights & Financial Overview as of February 2025

Here’s a summary of the key information extracted from the provided financial report section:

  1. Entity Information:
  • Company Name: Immunic, Inc.
  • CIK (Central Index Key): 0001280776
  • SEC File Number: 001-36201
  • EIN (Employer Identification Number): 56-2358443
  • Address: 1200 Avenue of the Americas, Suite 200, New York, NY 10036, USA
  • Contact Number: (332) 255-9818
  1. Filing Details:
  • Filing Type: 8-K (Current report)
  • Filing Date: February 20, 2025
  1. Stock Information:
  • Common Stock: Par value of $0.0001
  • Ticker Symbol: IMUX
  • Exchange: NASDAQ
  1. Financial Reporting Context:
  • Report Date: The context is as of February 20, 2025, indicating this report captures the company's financial situation on that specific date.
  • Units of Measurement:
    • Currency: USD
    • Shares: Denoted in shares
    • Stock Price: Expressed in USD per share
  1. Additional Context:
  • The document includes XML formatting indicative of XBRL (eXtensible Business Reporting Language), which is commonly used for financial reporting to enhance data interoperability.

Insights:

  • The filing type (8-K) suggests that the company may have reported significant events or changes that could impact shareholders or the market.
  • As this is a current report, it is crucial for investors to review this document for any material information affecting the company’s stock performance or strategic direction around the reporting date.
  • The provided information indicates a structured and formal reporting procedure, typical of public companies, ensuring compliance with SEC regulations.

Overall, this summarized data provides a glimpse into Immunic, Inc.'s corporate profile, recent filing activities, and essential stock-related information.